Harrow (HROW) Research & Development (2010 - 2026)
Harrow's (HROW) quarterly Research & Development came in at $5.9 million in Q1 2026, up 94.81% year-on-year from $3.0 million in Q1 2025, and down 49.71% quarter-over-quarter from $11.7 million in Q4 2025.
Harrow (HROW) Research & Development (2010 - 2026) Analysis & Trends
Harrow's Research & Development history runs 17 years deep, the most recent figure standing at $5.9 million for Q1 2026.
- On a quarterly basis, Research & Development rose 94.81% year-over-year to $5.9 million in Q1 2026; TTM through Mar 2026 was $23.8 million, a 81.65% increase from a year earlier, with the FY2025 full-year figure at $20.9 million, up 71.22% from the prior year.
- Research & Development eased to $5.9 million in Q1 2026 per HROW's latest filing, from $11.7 million in the prior quarter.
- Across five years, Research & Development topped out at $11.7 million in Q4 2025 and bottomed at $658000.0 in Q1 2022.
- The 5-year median for Research & Development is $2.3 million (2024), against an average of $2.9 million.
- Across the five-year window, Research & Development tumbled 87.35% in 2022 and jumped 374.54% in 2023, its largest moves.
- Year by year, Research & Development stood at $703000.0 in 2022, then surged by 374.54% to $3.3 million in 2023, then soared by 42.54% to $4.8 million in 2024, then soared by 146.54% to $11.7 million in 2025, then tumbled by 49.71% to $5.9 million in 2026.
- Per Business Quant, the three latest HROW Research & Development figures stand at $5.9 million (Q1 2026), $11.7 million (Q4 2025), and $3.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 138.20 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Harrow | 1.43 Bn | 1.34 Bn | 27.05 Mn | 5.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.90 Mn |
| Dec 31, 2025 | 11.72 Mn |
| Sep 30, 2025 | 3.32 Mn |
| Jun 30, 2025 | 2.87 Mn |
| Mar 31, 2025 | 3.03 Mn |
| Dec 31, 2024 | 4.76 Mn |
| Sep 30, 2024 | 2.27 Mn |
| Jun 30, 2024 | 3.05 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Dec 31, 2023 | 3.34 Mn |
| Sep 30, 2023 | 1.42 Mn |
| Jun 30, 2023 | 1.16 Mn |
| Mar 31, 2023 | 734,000.00 |
| Dec 31, 2022 | 703,000.00 |
| Sep 30, 2022 | 775,000.00 |
| Jun 30, 2022 | 914,000.00 |
| Mar 31, 2022 | 658,000.00 |
| Dec 31, 2021 | 3.94 Mn |
| Sep 30, 2021 | 6.13 Mn |
| Jun 30, 2021 | 425,000.00 |